Силимарин

Quick links to important sections

Силимарин

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Силимарин

What is Silymarin? (Overview)

Property Description
Active Ingredients Silybin (primary component), Silychristin, Silydianin
Common Origin Seeds of Milk Thistle (Silybum marianum)
Pharmacological Class Flavanolignans (Herbal extract)
Common Use Supportive treatment for chronic liver diseases
Key Property Antioxidant and anti-inflammatory activity

Silymarin is the collective name for a standardized extract derived from the seeds of the milk thistle plant, botanically known as Silybum marianum. Milk thistle has a long history of traditional use, specifically related to supporting liver and biliary health.

Composition and Classification

Silymarin is a complex mixture of active compounds called flavonolignans, a class of phytochemicals known for combining flavonoid and lignan structures. The most concentrated and therapeutically significant component within this complex is silybin, which itself is a mixture of two closely related molecules. Commercial extracts are typically standardized to ensure a high and consistent percentage of these active flavonolignans.

Status and Properties

Silymarin is widely recognized for its potent antioxidant and anti-inflammatory properties, which are the basis for its therapeutic effects. Globally, its regulatory status varies: it is approved in various countries for the supportive treatment of chronic inflammatory liver diseases and cirrhosis. Milk thistle fruit extract is recognized in certain regions for traditional use in supporting liver function. In the United States, it is primarily marketed and used as a dietary supplement.

What side effects are possible with Силимарин?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with Silymarin (Milk Thistle extract) as generally Uncommon or Rare, reflecting the nature of the product and available safety data. The documented side effects typically fall under specific System-Organ Classes (SOC) as defined in regulatory reports.


Documented Adverse Reactions and Frequencies

Adverse reactions are primarily associated with two system groups:

  • Gastrointestinal Disorders: This category includes digestive disturbances such as diarrhea, upset stomach, and nausea.
  • Skin and Subcutaneous Tissue Disorders: Reactions may include symptoms like rash, itching (pruritus), or hives (urticaria), which are sometimes manifestations of hypersensitivity.

Serious Safety Constraints

The most clinically significant safety constraint explicitly documented is the contraindication due to known hypersensitivity. Individuals with an allergy to milk thistle (Silybum marianum) or other plants in the Asteraceae/Compositae family (e.g., ragweed, daisies) should not use the product. Severe hypersensitivity reactions are considered a serious adverse reaction that requires cessation of use.


Population-Specific Safety Considerations

Official safety documents include specific constraints based on limited data in certain groups:

Population Group Regulatory Constraint
Pediatric Use Not recommended for use in children and adolescents under 18 years of age.
Pregnancy/Lactation Not recommended during pregnancy or breastfeeding due to insufficient safety data.

These constraints define the official safety context for the use of Silymarin.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that signs or symptoms of overdosage or poisoning with Silymarin have not hitherto been specifically observed. The acute toxicity of the product is noted as very low, resulting in a unique overdose profile.

Documented Manifestations and Risk

The primary risk associated with overdosage is categorized as the potential amplification of known undesirable effects. These effects may include nonspecific gastrointestinal disorders and a mild laxative effect. More serious manifestations requiring attention are linked to the potential for amplified hypersensitivity reactions. When severe symptoms such as dyspnoea (difficulty breathing) occur as a result of a suspected overdose, these outcomes necessitate immediate action.

Emergency Management and Action

The official procedure for managing an overdose is defined by the regulatory finding that no special antidote is known to exist. Consequently, management should consist only of symptomatic measures, which are recommended if necessary. Urgent medical attention is required when severe, life-threatening symptoms associated with the amplified undesirable effects manifest. No specific monitoring requirements or population-specific considerations (e.g., pediatric or elderly) are documented in the official overdose section of the prescribing information.

Therapeutic Uses of Силимарин

What Silymarin Treats: Main Uses and Benefits

Silymarin is traditionally applied to help support liver function in situations involving chronic physiological stress and provides supportive relief to the liver. This herbal extract is commonly used across conditions presenting with systemic or localized discomfort linked to organ-specific functional stress.


Therapeutic Focus and Relief

Silymarin is relevant in clinical settings for the complementary management of conditions involving inflammatory or irritative processes, such as chronic liver conditions. This usage is commonly used to help with conditions where symptoms may intensify temporarily and may assist with maintaining functional stability. The therapeutic domains of use also involve symptom clusters that may become intense or disruptive due to affected liver function. It is commonly used to help address symptoms related to physical discomfort, such as fatigue and general malaise, along with digestive disturbances like non-specific abdominal discomfort and poor appetite.

“It is commonly used to help address symptom clusters that may become intense or disruptive due to affected liver function.”

Silymarin is also applied in scenarios where additional symptomatic support is needed following known exposure to specific hepatotoxic agents or environmental toxins. In these contexts, it supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Digestive Disturbances


Regulatory References

  1. Health Canada Natural Health Products Database

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Silymarin (Силимарин) — Official Regulatory Information

Official regulatory documents define the population eligibility for Silymarin by identifying specific groups that are either approved for use, formally contraindicated, or subject to official restrictions due to a lack of safety data.

Category Official Regulatory Status
Populations for whom use is allowed Adults (generally 18 years and older) for supportive use under labeled conditions.
Populations for whom use is contraindicated Individuals with hypersensitivity to the Milk Thistle plant (Silybum marianum) or other plants in the Asteraceae family. Patients with hormone-dependent malignant tumors (e.g., breast, ovarian, uterine carcinoma) are restricted due to the potential estrogen-like effect of the substance.
Age-related eligibility rules Not Recommended for children and adolescents (typically under 18 years) as official data on safety and efficacy are considered insufficient or not established.
Pregnancy and lactation eligibility status Use is not recommended during pregnancy and breastfeeding due to insufficient data to establish safety in these special populations.

Eligibility Classifications (High-Level) The official eligibility profile uses the formal regulatory classifications of Contraindicated (absolute prohibition based on risk) and Not Recommended (precautionary exclusion based on insufficient data). These official statements restrict the eligible population strictly to adults who do not meet any formal contraindication criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clinical and laboratory studies indicate that silymarin has the potential to interact with certain medications, primarily by affecting drug-metabolizing enzymes and transport proteins in the body. The active components of silymarin have demonstrated the ability to inhibit Cytochrome P450 (CYP) enzymes, notably CYP3A4 and CYP2C9, and the UDP-glucuronosyltransferase (UGT) 1A1 enzyme. These enzymes are responsible for the breakdown of many common prescription drugs.

Officially documented interactions include:

  • Simeprevir: Coadministration is not recommended and should be avoided, as silymarin may significantly increase the plasma concentration of this Hepatitis C medication, potentially raising the risk of adverse effects.
  • Raloxifene: Silymarin may alter the liver's processing of this osteoporosis medication, which could lead to increased levels of Raloxifene in the bloodstream.
  • Warfarin and other CYP2C9 substrates: Due to its inhibitory effect on the CYP2C9 enzyme, silymarin may increase the blood levels of drugs metabolized by this pathway, such as the anticoagulant Warfarin. Increased monitoring of blood clotting parameters may be necessary.
  • Diabetes medications: Silymarin may have blood sugar-lowering effects, necessitating caution and close monitoring when used concurrently with prescription medications for diabetes.

While laboratory models suggest the potential for interaction with numerous other drugs that are substrates for CYP enzymes or transporters like P-glycoprotein, the clinical significance of these effects at typical human doses is often considered minor or has not been conclusively established in human trials.

Mechanism of Action

️ Induction of Cellular Defense and Redox Control

This mechanism focuses on activating the Nrf2 pathway to enhance the cell's intrinsic capacity to neutralize free radicals and manage oxidative stress. By upregulating endogenous antioxidant enzymes, this action contributes to membrane stabilization and a reduction in molecular damage.

Modulation of Inflammatory and Fibrotic Signaling

The drug modulates the signaling pathways contributing to chronic tissue degradation by inhibiting NF-κB activation, which dampens the synthesis of pro-inflammatory mediators. Simultaneously, it suppresses hepatic stellate cell activation, a key mechanism in reducing the deposition of extracellular matrix components.

Support for Hepatocyte Integrity and Repair

This domain supports the physical structure and regenerative mechanisms of the liver cell by two distinct actions: stabilizing the outer cell membrane to physically restrict the entry of certain toxins, and stimulating ribosomal RNA (rRNA) synthesis to support protein synthesis required for cellular renewal and proliferation.

Dosage and Administration Information

Instruction Map: How to use Silymarin — Administration Guidelines


Administration Scope

Instruction Detail
Route of administration Oral administration is the documented route for all approved dosage forms, including capsules and extracts.
Dosing schedule Standard regimens use divided daily doses, typically ranging from 140 mg to 420 mg of silymarin daily. A common established regimen is 140 mg three times daily.
Timing in relation to meals (if applicable) Capsules must be swallowed whole with liquid (e.g., water). Certain traditional forms may be recommended for use before meals.
Preparation requirements (if applicable) The medication must be taken as the specified unit dose, and the total daily dose must not be exceeded.
Age-group administration rules Use in children and adolescents under 18 years of age is not recommended due to a lack of established clinical data.
Special procedural conditions For liver function support, guidelines cite use for a minimum of 3 weeks to observe beneficial effects.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral (Capsules, extracts).
Frequency pattern Divided daily dosing (Two or three times per day, BID or TID).
Regulatory basis Standardized therapeutic protocols and official product documentation.
Use-context constraints Duration varies (short-term for symptomatic use or long-term for chronic conditions); pediatric exclusion applies.

Resulting Procedural Structure

General Step Sequence:

  • The prescribed dose of the extract is taken orally.
  • Administration is performed in divided doses (two or three times) over the course of the day.
  • The medication is to be used for a duration that may extend to long periods, often with a minimum period of use specified to register effects.

Connection to the Overall Use Protocol

The instructions define a clear oral administration protocol utilizing divided daily dosing to ensure consistent intake of the active extract. This structure establishes explicit dose limits and age exclusions, standardizing how the product is used in practice. The inclusion of variable duration patterns—from short-term symptomatic use to long-term chronic support—reflects the range of its documented application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Silymarin

Evidence for Use in Chronic Liver Disease (General)

The evidence base for Silymarin, which was studied for use in Chronic Liver Disease (CLD), is primarily built upon a foundation of randomized controlled trials (RCTs) and systematic reviews that combine the data from those trials. Research has researched Silymarin in people dealing with various long-term liver issues, including chronic viral hepatitis and fatty liver conditions. In these studies, researchers monitored several outcomes, particularly biochemical markers like the liver enzymes ALT and AST. Monitoring these markers is a focus of research to track the liver’s functional status. Findings from these studies describe the changes measured in liver enzymes, although the results can vary across different patient groups and trial designs. Analysis of the overall evidence base often highlights inconsistent findings when assessing definitive clinical endpoints related to the course of chronic liver disease. This variation in reported outcomes means evidence quality varies and is limited, particularly when looking at results over short study durations.


Evidence for Specific Liver Conditions: Cirrhosis and NAFLD

Research explored Silymarin in people with more clearly defined conditions, such as Alcoholic Liver Cirrhosis and Non-Alcoholic Fatty Liver Disease (NAFLD). For alcoholic cirrhosis, some older, high-duration RCTs where long-term status (including liver-related outcomes) was monitored over several years. However, subsequent analyses combining these trials described inconsistent findings, and the evidence regarding the long-term impact on survival remains uncertain due to inconsistent findings. For individuals with NAFLD, studies monitored outcomes related to metabolic factors and liver enzyme changes. Findings from these studies reported changes measured in biochemical markers, but certainty remains low as findings related to key histological endpoints have been inconsistent across trials.


Evidence for Symptom Support and Patient Outcomes

Silymarin was studied for outcomes related to symptoms associated with daily-life functioning when living with chronic disease. This research explored short-term symptom changes using methods that assess patient-reported outcomes (PROs), monitoring reports of general malaise, fatigue, and non-specific digestive discomfort over relatively short duration intervals. These findings describe patterns observed in the studies regarding these subjective symptoms. Research provides insight into short-term changes, but these findings are often derived from secondary endpoint analyses; the study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Силимарин (FAQ)


Q: Is Силимарин used only for liver problems?

A: Silymarin is officially recognized for the supportive treatment of chronic liver diseases in many regulatory documents. However, the compound's mechanism, which involves antioxidant and anti-inflammatory properties, is broader than just liver function. These properties are the basis for its traditional use in various health contexts beyond the liver.


Q: How quickly can I expect results from Силимарин?

A: Official guidelines indicate that a minimum use duration of approximately three weeks is often cited as the period required to observe beneficial effects. The time it takes for a person to subjectively perceive any results can vary widely among individuals. This expectation is based on the general timelines noted in clinical research.


Q: Is Силимарин a prescription drug or an over-the-counter supplement?

A: The regulatory status of Silymarin is not consistent worldwide. In some countries, it is classified and approved as a medicine intended for the supportive treatment of certain chronic liver issues. Conversely, in other major markets, it is primarily available to the public and marketed as a dietary supplement.


Q: Why do some people say it helps with digestion?

A: Historically, the traditional use of milk thistle was sometimes associated with an improvement in general digestive discomfort. However, official product information indicates that the most commonly reported non-serious adverse reactions are gastrointestinal disorders, such as diarrhea and nausea. This reflects that digestive upset is also a possibility based on documented safety data.


Q: Are there any serious side effects to watch out for?

A: Regulatory documents identify severe hypersensitivity (allergic reaction) as the most clinically significant safety concern. This includes a documented contraindication for anyone with a known allergy to milk thistle or plants in the daisy family. A severe allergic reaction is documented as requiring the immediate cessation of the product.


Q: Is there a difference between the extract and the whole herb?

A: Silymarin refers specifically to the standardized extract derived from the milk thistle plant. This extract contains a guaranteed, concentrated amount of active substances known as flavonolignans. In contrast, the whole herb or unrefined seeds do not contain a guaranteed, standardized concentration of these active components.


Q: Is there scientific proof that Силимарин is effective?

A: Research evidence includes numerous studies and randomized controlled trials (RCTs) examining Silymarin's use for chronic liver conditions. While many studies report favorable changes in biochemical markers, such as liver enzymes, the findings are often described as inconsistent. Regulatory assessments often conclude that the evidence quality varies and that definitive long-term clinical conclusions are uncertain.


Q: Why is Силимарин sold in different strengths (e.g., 100mg, 150mg)?

A: Products are sold in different strengths to help users meet the total daily dosage range established in official guidelines. Standard regimens often require divided daily doses, and the various strengths allow for flexibility in reaching the reported intake amount.


Q: Can Силимарин affect the results of blood tests?

A: Studies frequently monitor the effect of Silymarin on biochemical markers in the blood, such as liver enzymes (ALT and AST). Furthermore, due to its interaction potential with certain drugs, official guidelines may require increased monitoring of specific tests, such as those measuring blood clotting parameters.


Q: What is the shelf life of a Силимарин product?

A: The specific shelf life or expiry date is printed directly on the product's container or packaging. To ensure the product maintains its stability and integrity until this date, it is designed to be stored according to label instructions. These instructions usually specify keeping it protected from light and moisture and not exceeding a certain temperature (e.g., 25 C or 30 C).


Q: What is the significance of the standardization percentage on the label?

A: The standardization percentage, often listed as the content of flavonolignans or silybin, is a measure of product quality and consistency. It guarantees that a minimum, effective amount of the active compound is present in the extract. The standardization is intended to align the product’s composition with that studied in supportive treatment research.


Q: Can men and women take Силимарин for the same reasons?

A: The supportive use of Silymarin is generally applicable to all adults. However, a significant restriction applies to women with a history of hormone-dependent malignant tumors (such as certain breast or ovarian cancers). Official guidelines state that use is restricted for this group due to the substance’s potential estrogen-like effect.


Q: Does Силимарин need to be taken with food?

A: The standard instruction is to swallow the capsule whole with a liquid. While certain historical or traditional uses suggested taking it before meals, product labels for the standardized extract often do not provide a general requirement regarding food consumption. The best approach involves observing the specific timing instruction provided on the product label.


Q: Does Силимарин have any effect on cholesterol levels?

A: Some clinical research that has examined Silymarin in the context of liver disease or metabolic disorders has monitored lipid profile markers. These reports sometimes mention changes in markers like cholesterol and triglycerides, though this is not listed as a primary or guaranteed effect.


Q: Does Силимарин interact with birth control pills?

A: Silymarin is known to inhibit certain drug-metabolizing enzymes in the liver, such as CYP3A4. Because many oral contraceptives are processed by this specific enzyme pathway, a potential for interaction exists. Product information generally advises observing caution regarding any prescription medications being used concurrently.


Q: Can Силимарин be taken with pain relievers (e.g., ibuprofen)?

A: Silymarin's effect on liver enzymes, such as CYP2C9 and CYP3A4, means it could potentially alter the way the body processes other drugs. Because many non-steroidal anti-inflammatory drugs (NSAIDs) and pain relievers are metabolized by these enzymes, awareness of this potential interaction profile is advised.


Q: Does alcohol consumption affect how Силимарин works?

A: Clinical research often requires that study participants adhere to strict guidelines concerning alcohol consumption. Furthermore, Silymarin is studied specifically for its potential protective mechanisms against the harmful effects of certain toxins on the liver, including those produced during ethanol metabolism.


Q: Are there any clinical trials on Силимарин for conditions other than liver disease?

A: While the primary use is for liver support, studies have been conducted on Silymarin’s effects in other conditions, leveraging its antioxidant and anti-inflammatory properties. These areas of research include metabolic support and specific conditions like diabetic nephropathy.


Q: What should I do if I miss a dose of Силимарин?

A: According to official product information, if a dose is missed, it can be taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the recommendation is to skip the missed dose entirely. The guidance specifies not taking a double dose to compensate for the one that was missed.


Q: Is it normal to feel a mild headache when starting Силимарин?

A: Official product information lists headache as a rare or uncommon adverse reaction that may occur in some individuals. Other non-serious reactions, such as mild dizziness or skin reactions, are also sometimes reported.


Q: Can Силимарин make you tired or dizzy?

A: Dizziness is listed as an uncommon or rare adverse reaction in some product information. While fatigue is also sometimes mentioned in side effect reports, it is also a common symptom of the chronic conditions for which the product is used.


Q: Can people with kidney problems use Силимарин?

A: Regulatory documents generally state that no dose adjustment is typically necessary for adults with kidney problems. Furthermore, due to its properties, research has explored the use of Silymarin in specific kidney conditions, such as diabetic nephropathy.


Q: How long does it take for Силимарин to leave the system?

A: Pharmacokinetic data, which tracks the movement of the substance in the body, indicates that the active constituent, silybin, has an elimination half-life of approximately 6.3 hours. The half-life is the time required for the amount of the drug in the body to be reduced by half.


Q: Do you need to cycle Силимарин (take breaks)?

A: Official guidelines support Silymarin use that can extend to long periods. Furthermore, preclinical safety data generally indicates a low toxicity profile, suggesting the substance can be administered safely for extended durations without the requirement for planned breaks or 'cycling.'


Q: Does Силимарин affect blood pressure?

A: While an effect on blood pressure is not documented as a common adverse reaction, its use has been monitored in some studies involving patients with co-existing conditions like hypertension. These studies sometimes note effects on metabolic factors and blood pressure readings.


Q: Is it okay to take Силимарин with a multivitamin?

A: The use of a multivitamin taken at standard recommended doses is generally permitted in the context of clinical trials involving Silymarin. This is supported by the fact that some combination products containing both Silymarin and multivitamins are regulated and available for use.


Q: Does Силимарин cause weight gain or weight loss?

A: Weight changes are not listed as common side effects. However, some regulatory-based product information mentions an increase in body weight and appetite in patients whose overall health was initially impaired by underlying liver conditions.


Q: Is there any evidence Силимарин helps with skin conditions?

A: Research has investigated the antioxidant and anti-inflammatory properties of Silymarin in laboratory and animal models related to dermatology. This research has explored potential supportive uses for skin conditions, including photoprotection against damage caused by UV radiation.


Q: Why do doctors mention Силимарин for mushroom poisoning?

A: Silymarin is frequently referenced in medical literature for its potential role as a supportive treatment in cases of acute poisoning, specifically from the deathcap mushroom (Amanita phalloides). This is due to the substance’s ability to interfere with the liver uptake of the mushroom’s damaging toxins.

How should Силимарин be stored and disposed of?

How to Store and Dispose of Silymarin

Official regulatory documents define strict conditions for storing and disposing of silymarin-containing products to ensure stability and public safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at a temperature not exceeding 25 C or 30 C, as specified by the product label.
Protection Keep the container tightly closed and protect the product from light and moisture.
Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused silymarin products must not be disposed of using household waste or by flushing them down the drain. Disposal must strictly follow local regulations for pharmaceutical waste. This often involves returning the product to a pharmacy or using designated collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Силимарин found in:

A-Z Index: